ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
EMA accepts marketing application for Spinal Muscular Atrophy treatment
August 20, 2020The European Medicines Agency (EMA) has accepted the marketing authorisation application for Evrysdi™ (risdiplam) as a treatment of spinal muscular atrophy (SMA). -
Roche gets US FDA approval for Evrysdi to treat spinal muscular atrophy
August 12, 2020In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA. -
Roche gets FDA nod for Evrysdi to treat spinal muscular atrophy
August 11, 2020Roche has secured approval from the US Food and Drug Administration (FDA) for its Evrysdi (risdiplam) to treat spinal muscular atrophy (SMA) in adults and children aged two months of age and older. -
Genentech secures FDA approval for Evrysdi to treat SMA
August 11, 2020Roche unit Genentech has received approval from the US Food and Drug Administration (FDA) for Evrysdi (risdiplam) to treat spinal muscular atrophy (SMA) in patients aged two months and above.
Pharma Sources Insight January 2025
